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Role of Ashwangandha (Withania somnifera) in immune modulation: 
Proposed influence in Immune-regulation 
Subhasis Chattopadhyay and Robert E. Cone* 
Department of Immunology, Connecticut Lions Vascular Eye Center, 
University of Connecticut Health Center, 
Farmington, CT 06030, USA 
Abstract: The immune system evolved to protect organisms from an infinite variety of disease-causing agents but to avoid harmful re- 
sponses to self. However, such a powerf~l defense mechanism requires regulation. Immune regulation includes homeostatic and cell- 
mediated targeted mechanisms to the activation, differentiation and function of antigen-triggered immuno-competent cells and irnmuno- 
regulatory cells. The regulation of the immune system has been a major challenge for the management of autoimmune disorders, tumor 
immunity, infectious diseases and organ transplants. However, irnmuno-modulatory procedures used by modern medicine to induce 
immunoregulatory function have deleterious side effects. Ashwangandha (Withania somnifera), an herb used in Ayurvedic medicine is 
being tested and used in experimental and clinical cases with potential immuno-modulatory functions without any side effects. Here we 
propose future usages of Ashwangandha for immuno-regulatory function in translational research. 
Ashwangandha: an immunoregulatory herb 
Immune protective mechanisms include the elaboration of potent inflammatory molecules, antibodies, and 
killer cell activation - which together not only destroy invading microorganisms, pathogenic autoreactive 
I f 
cells, and tumors, but also may mortally injure normal cells. Accordingly, the immune response is tightly regu- 
lated by immuno-regulatory cells, cytokines and external influences. 
Withania somnifera Dunal (Ashwagandha), also known as Indian ginseng, belongs to the family Solanaceae, 
which is distributed throughout India. It is widely used in the Ayurvedic system of medicine to treat tumors, 
inflammation, arthritis, asthma, and hypertension (1). Ashwangandha has been used as an immunostimulant 
and as a dietary supplement (1, 2). Although it has been reported to selectively enhance T helper 1 (Thl) 
immune responses (2, 3), Ashwangandha also has anti-inflammatory function (4). 
Understanding the immuno-modulatory mechanisms of Ashwangandha can provide insight into immune func- 
tion and regulation that could further help in immunoregulatory procedures. Chemical investigation with the 
extract of roots and leaves of Withainia somnifera (WS) have yielded bioactive withanolides, which inhibit 
cyclooxygenase enzymes, lipid peroxidation, and the proliferation of tumor cells (reviewed in 5). It has been 
reported that WS extract preferentially reduces inflammatory processes by inactivating nuclear factor-kappaB 
(NF-kB) activation, by inducing cellular death by apoptosis, inhibiting inflammation and abolishing osteoclas- 
togenesis through suppression of NF-kB activation and NF-kB-regulated gene expression (5). Similar studies 
show that the leaf extract of WS, as well as its major constituent withaferin A (WA), potently inhibits NF-kB 
activation by preventing the tumor necrosis factor-induced activation of I-kappaB kinase beta (6). This study 
indicates that pure WA or WA-enriched WS extracts can be considered as a novel class of NF-kB inhibitors, 
which hold promise as novel anti-inflammatory agents for the treatment of various inflammatory disorders 
andlor cancer. It has been proposed that the antiproliferative, proapoptotic, anti-invasive, antiosteoclasto- 
genic, antiangiogenic, antimetastatic, radiosensitizing, antiarthritic, and cardioprotective effects assigned to 
withanolide may be mediated in part through the suppression of NF-kB and NF-kB-regulated gene products 
Recently, withaferin A (made from the crushed air-dried leaves of Withania somnifera Dun.) was used to in- 
duce apoptosis in parasitic protozoa Lesihmania donovani, which acts as a novel protein kinase inhibitor and 
it is facilitated by apoptotic topoisomerase I-DNA complex (7). The anti-microbial effect of WS was also 
I 
shown in a prophylactic administration of WS extract, which increases host resistance in Listeria monocyto- 
genes- infected mice (8). Moreover, the therapeutic role of Withania has potential usage in inflammation and 
I 
the patho-physiology of immune regulation. In summary the potential roles of Ashwangandha in immune 
I 
i 
modulation is shown in Fig. 1 along with its curative usage for different diseases. i 
4 
Ashwangandha: the future candidate for experimental and clinical immunology research I 
The future lines of basic and translational research with Withania must enroll the investigation for immu- 1 
noregulatory cells, which are the cellular feedback regulators of an Immune response. ! 
The involvement of such immuno- regulatory cells induced by WS might have several functions: such as regu- 
lating antigen presentation and an immunosuppressive microenvironment along with a physiological cytokine 
milieu for an effector T cell function. It is intriguing that the treatment of Withania induces a Thl cell-mediated 
immune response and an elevation of IgG2a- mediated humoral immune responses (2, 3). In addition, the 
aqueous suspension of WS shows anti-inflammatory and immunosuppressive effects by inhibiting the comple- 
ment system, mitogen- induced lymphocyte proliferation and delayed type hypersensitivity (DTH) in rats (4). 
Although in this investigation no effect on the humoral response was observed, others have reported elevated 
levels of IgG2a over lgGl in the WS- treated BALBIc mice (3). There may be differential effect(s) andlor alter- 
native responsiveness of WS treatment between mouse strains and rats for immune activation versus suppres- 
sion. Accordingly, a comparative study of different forms of WS extract is warranted towards the understanding 
of respective immune modulation in different contexts. The induction of regulatory T cells (Treg) and the im- 
mune suppression of effector T cell functions have been reported by others and us in tumor immunity (9-12) 
and ocular immune privilege (13, 14). However, the effect of Withania on the immuno-regulatory cellular re- 
sponse has not been tested yet. Accordingly, this natural product is a future candidate that might address the 
cross-talk between the effector immune cell response and the influence of a Treg response. 
Finally, investigations into the use of preparation of Withania somnifera, in concert with the holistic Ayurvedic 
approaches to treat immunoregulatory disorders may impact on several forms of autoimmune diseases, tumor 
progression, parasitic infection, inflammation, organ transplantation and stress. 
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